JP2016528217A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016528217A5 JP2016528217A5 JP2016529868A JP2016529868A JP2016528217A5 JP 2016528217 A5 JP2016528217 A5 JP 2016528217A5 JP 2016529868 A JP2016529868 A JP 2016529868A JP 2016529868 A JP2016529868 A JP 2016529868A JP 2016528217 A5 JP2016528217 A5 JP 2016528217A5
- Authority
- JP
- Japan
- Prior art keywords
- chemotherapeutic agent
- nucleoside analog
- combination
- taxane
- activated prodrug
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 206010021143 Hypoxia Diseases 0.000 claims 10
- 230000007954 hypoxia Effects 0.000 claims 10
- 229940002612 prodrug Drugs 0.000 claims 10
- 239000000651 prodrug Substances 0.000 claims 10
- 229940123237 Taxane Drugs 0.000 claims 9
- 239000002246 antineoplastic agent Substances 0.000 claims 9
- 229940127089 cytotoxic agent Drugs 0.000 claims 9
- 239000002777 nucleoside Substances 0.000 claims 9
- 150000003833 nucleoside derivatives Chemical class 0.000 claims 9
- 239000003814 drug Substances 0.000 claims 7
- DKPFODGZWDEEBT-QFIAKTPHSA-N taxane Chemical class C([C@]1(C)CCC[C@@H](C)[C@H]1C1)C[C@H]2[C@H](C)CC[C@@H]1C2(C)C DKPFODGZWDEEBT-QFIAKTPHSA-N 0.000 claims 7
- 229960001592 paclitaxel Drugs 0.000 claims 4
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 claims 4
- 108010058566 130-nm albumin-bound paclitaxel Proteins 0.000 claims 3
- 206010028980 Neoplasm Diseases 0.000 claims 3
- 201000011510 cancer Diseases 0.000 claims 3
- SDUQYLNIPVEERB-QPPQHZFASA-N gemcitabine Chemical compound O=C1N=C(N)C=CN1[C@H]1C(F)(F)[C@H](O)[C@@H](CO)O1 SDUQYLNIPVEERB-QPPQHZFASA-N 0.000 claims 3
- 229960005277 gemcitabine Drugs 0.000 claims 3
- 201000008129 pancreatic ductal adenocarcinoma Diseases 0.000 claims 2
- 229930012538 Paclitaxel Natural products 0.000 claims 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 201000002528 pancreatic cancer Diseases 0.000 claims 1
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 1
- 230000003442 weekly effect Effects 0.000 claims 1
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361859152P | 2013-07-26 | 2013-07-26 | |
| US61/859,152 | 2013-07-26 | ||
| US201361887873P | 2013-10-07 | 2013-10-07 | |
| US61/887,873 | 2013-10-07 | ||
| US201461994295P | 2014-05-16 | 2014-05-16 | |
| US61/994,295 | 2014-05-16 | ||
| PCT/US2014/047885 WO2015013448A1 (en) | 2013-07-26 | 2014-07-23 | Treatment of pancreatic cancer with a combination of a hypoxia-acti vated prodrug and a taxane |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2016528217A JP2016528217A (ja) | 2016-09-15 |
| JP2016528217A5 true JP2016528217A5 (cg-RX-API-DMAC10.html) | 2017-08-31 |
Family
ID=51299053
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016529868A Pending JP2016528217A (ja) | 2013-07-26 | 2014-07-23 | 低酸素活性化プロドラッグおよびタキサンの組合せを用いた膵臓癌の治療 |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US20160158253A1 (cg-RX-API-DMAC10.html) |
| EP (1) | EP3024490A1 (cg-RX-API-DMAC10.html) |
| JP (1) | JP2016528217A (cg-RX-API-DMAC10.html) |
| CN (1) | CN105792845A (cg-RX-API-DMAC10.html) |
| WO (1) | WO2015013448A1 (cg-RX-API-DMAC10.html) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10940112B2 (en) | 2016-05-04 | 2021-03-09 | L.E.A.F. Holdings Group Llc | Targeted liposomal gemcitabine compositions and methods thereof |
| CN106279321A (zh) * | 2016-08-09 | 2017-01-04 | 南京医科大学 | 吉西他滨ProTide乏氧活化前药及其应用 |
| EP3523740A1 (en) * | 2016-10-05 | 2019-08-14 | Koninklijke Philips N.V. | Patient monitoring systems and methods |
| JP7500536B2 (ja) * | 2018-03-23 | 2024-06-17 | アデノサイト リミテッド | 強化された細胞病理学的細胞採取のための細胞および／または組織片の剥離を誘導する方法 |
| CN110680824A (zh) * | 2018-07-05 | 2020-01-14 | 深圳艾欣达伟医药科技有限公司 | 埃夫索胺的抗癌医药用途 |
| JP7762796B2 (ja) | 2021-08-27 | 2025-10-30 | アセンタウィッツ ファーマシューティカルズ リミテッド | Ｐａｒｐ阻害剤に耐性のある患者のｔｈ－３０２による治療 |
| WO2023025291A1 (zh) | 2021-08-27 | 2023-03-02 | 深圳艾欣达伟医药科技有限公司 | 冻干制剂溶液及冻干制剂、方法和用途 |
| US20250186468A1 (en) | 2022-03-15 | 2025-06-12 | Ascentawits Pharmaceuticals, Ltd. | Method for treating patient with brca-mutated cancer |
| EP4509127A4 (en) | 2022-04-15 | 2026-07-15 | Ascentawits Pharmaceuticals Ltd | CANCER TREATMENT METHOD USING TH-302 ALONE OR IN COMBINATION WITH A PARP INHIBITOR |
| EP4529926A4 (en) | 2022-05-23 | 2026-07-01 | Ascentawits Pharmaceuticals Ltd | CANCER TREATMENT METHOD BY COMBINATION OF AN ALKYLATING AGENT PRODRUGATION AND A CELL CYCLE INHIBITOR |
| CN119894521A (zh) | 2022-09-22 | 2025-04-25 | 深圳艾欣达伟医药科技有限公司 | 乏氧激活的化合物在制备治疗癌症患者的药物中的用途 |
| EP4674418A1 (en) | 2023-02-27 | 2026-01-07 | Ascentawits Pharmaceuticals, Ltd. | Solution, freeze-dried formulation, freeze-dried formulation unit package, injection, and injection preparation method |
| EP4755396A1 (en) | 2023-07-28 | 2026-06-10 | Ascentawits Pharmaceuticals, Ltd. | Treatment of p53 gene mutation or defect negative cancer and tumor patients |
| CN121985960A (zh) | 2023-10-18 | 2026-05-05 | 深圳艾欣达伟医药科技有限公司 | 治疗p53基因突变阴性、kras基因突变阳性、brca突变阳性患者 |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4526988A (en) * | 1983-03-10 | 1985-07-02 | Eli Lilly And Company | Difluoro antivirals and intermediate therefor |
| WO1993021173A1 (en) * | 1992-04-17 | 1993-10-28 | Abbott Laboratories | Taxol derivatives |
| US5439686A (en) | 1993-02-22 | 1995-08-08 | Vivorx Pharmaceuticals, Inc. | Methods for in vivo delivery of substantially water insoluble pharmacologically active agents and compositions useful therefor |
| GB9909612D0 (en) | 1999-04-26 | 1999-06-23 | Cancer Res Campaign Tech | N-protected amines and their use as prodrugs |
| NZ521851A (en) | 2002-10-08 | 2005-02-25 | Auckland Uniservices Ltd | Nitroaniline-based unsymmetrical mustard alkylating agents for gene dependent enzyme prodrug therapy |
| ZA200507752B (en) | 2003-03-28 | 2007-01-31 | Threshold Pharmaceuticals Inc | Compositions and methods for treating cancer |
| AU2004285831B2 (en) | 2003-10-31 | 2011-09-15 | Auckland Uniservices Limited | Novel nitrophenyl mustard and nitrophenylaziridine alcohols and their corresponding phosphates and their use as targeted cytotoxic agents |
| ZA200800314B (en) | 2005-06-29 | 2009-09-30 | Threshold Pharmaceuticals Inc | Phosphoramidate alkylator prodrugs |
| JP2009510165A (ja) | 2005-10-03 | 2009-03-12 | ジェネティックス ファーマシューティカルズ， インク． | 低酸素細胞を選択的に枯渇させるための方法 |
| US8552048B2 (en) | 2006-12-26 | 2013-10-08 | Threshold Pharmaceuticals, Inc. | Phosphoramidate alkylator prodrugs for the treatment of cancer |
| WO2010048330A1 (en) | 2008-10-21 | 2010-04-29 | Threshold Pharmaceuticals, Inc. | Treatment of cancer using hypoxia activated prodrugs |
| KR20130088116A (ko) * | 2010-06-04 | 2013-08-07 | 아브락시스 바이오사이언스, 엘엘씨 | 췌장암의 치료 방법 |
| AU2011276590A1 (en) | 2010-06-28 | 2013-01-31 | Threshold Pharmaceuticals, Inc. | Treatment of blood cancer |
| RU2597844C2 (ru) | 2010-07-12 | 2016-09-20 | Тресхолд Фармасьютикалз, Инк. | Введение гипоксически активируемых пролекарств и средств, препятствующих ангиогенезу, для лечения рака |
| MX2013011199A (es) * | 2011-04-01 | 2013-12-16 | Threshold Pharmaceuticals Inc | Metodos para tratar el cancer. |
| JP2014510795A (ja) | 2011-04-15 | 2014-05-01 | スレッショルド ファーマシューティカルズ、インク． | 経口投与用の単位用量形態物 |
| EP2793882A4 (en) | 2011-12-22 | 2015-04-29 | Threshold Pharmaceuticals Inc | ADMINISTRATION OF HYPOXIA-ACTIVATED PRODRUGS IN COMBINATION WITH CHK1 INHIBITORS FOR THE TREATMENT OF CANCER |
| EP2793899A4 (en) | 2011-12-22 | 2015-06-17 | Threshold Pharmaceuticals Inc | HYPOXIA-ACTIVATED PRODRUGS AND MTOR INHIBITORS FOR CANCER TREATMENT |
| JP6360438B2 (ja) | 2012-02-21 | 2018-07-18 | モレキュラー テンプレーツ，インコーポレイテッド | 癌の治療 |
-
2014
- 2014-07-23 US US14/907,190 patent/US20160158253A1/en not_active Abandoned
- 2014-07-23 CN CN201480053041.5A patent/CN105792845A/zh active Pending
- 2014-07-23 JP JP2016529868A patent/JP2016528217A/ja active Pending
- 2014-07-23 WO PCT/US2014/047885 patent/WO2015013448A1/en not_active Ceased
- 2014-07-23 EP EP14748448.9A patent/EP3024490A1/en not_active Withdrawn
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL254377B (en) | Selective akr1c3 reductase activated prodrugs and their use for treating cancer patients | |
| EA201890272A1 (ru) | Axl-специфические конъюгаты антитело-лекарственное средство для лечения рака | |
| BR112018010671A8 (pt) | dispositivos e métodos de distribuição de fármaco com mudança de forma | |
| HK1216853A1 (zh) | 治療胰腺癌的方法 | |
| HUE055873T2 (hu) | Arany klaszter (AuCs) vagy AuCs-t tartalmazó anyagok alkalmazása glaukóma megelõzésére és/vagy kezelésére szolgáló gyógyszer elõállítására | |
| JP2014141525A5 (cg-RX-API-DMAC10.html) | ||
| MA52257A (fr) | Compositions pharmaceutiques comprenant blautia et leur administration orale | |
| IL285440A (en) | Oral compositions containing octreotide in combination with other therapeutic agents for tretment of acromegaly | |
| MX2015010791A (es) | Metodos para tratar el cancer y prevenir la resistencia a farmacos. | |
| IL258246B (en) | Isolidine compound, pharmaceutical compositions comprising same, their combinations with therapeutic agents for use in the treatment of cancer | |
| MA39765A (fr) | Formulation pharmaceutique d'un inhibiteur de la kinase pan-raf, ses procédés de préparation, et procédés d'utilisation | |
| HUE044317T2 (hu) | Szubsztituált 2-tioxo-imidazolin-4-on vegyületek és spiro-analógjaik, rákellenes alkotórész, gyógyászati készítmény, orvosi preparátum, eljárás prosztatarák kezelésére | |
| JP2018522028A5 (cg-RX-API-DMAC10.html) | ||
| RU2017141536A (ru) | Замещенные производные индол-5-ола и их терапевтические применения | |
| NZ716765A (en) | Pharmaceutical combinations for the treatment of cancer | |
| IL267775A (en) | Combined treatment with a Lantrin-1 interfering drug and immune checkpoint inhibitor drugs | |
| HUE066216T2 (hu) | Ftalazin származékok, mint a parp1, parp2 és/vagy tubulin inhibitorai, hasznosak a rák kezelésében | |
| MX2022000394A (es) | Combinaciones terapeuticas de paclitaxel oralmente administrado y un inhibidor de la bomba de p-glicoproteina (p-gp) para el tratamiento del cancer. | |
| CY1123539T1 (el) | Παραγων κατα των ογκων που περιλαμβανει ενυδρη υδροχλωρικη ιρινοτεκανη | |
| MA43178A (fr) | Analogues d'épothilone, procédés de synthèse, procédés de traitement, et conjugués médicamenteux de ceux-ci | |
| EP3365026A4 (en) | ANTICIPATING AND INFLAMMATORY THERAPEUTICS AND METHOD THEREFOR | |
| HUE047272T2 (hu) | Gyógyászati kompozíció rák kezelésére és/vagy megelõzésére | |
| JP2019518052A5 (cg-RX-API-DMAC10.html) | ||
| NZ725067A (en) | Anti-tumor agent containing anti-tumor platinum complex, and anti-tumor effect enhancer | |
| ZA201901004B (en) | High drug loaded tablet composition for treating hiv |